Pfizer, Celltrion say data backs switch to Remicade biosimilar
admin 31st October 2017 Uncategorised 0Pfizer and Celltrion Healthcare have unveiled new data showing that switching patients with Crohn’s disease from Remicade to biosimilar Inflectra showed comparable efficacy, safety and tolerability over a 24-week period.
More: Pfizer, Celltrion say data backs switch to Remicade biosimilar
Source: News